• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ear­ly-stage in­vestor Syn­cona read­justs pri­or­i­ties due to bleak biotech mar­ket

3 weeks ago
Financing
Startups

FDA OKs new la­bel ex­pan­sions for Dupix­ent and In­cyte's Mon­ju­vi

3 weeks ago
News Briefing

En­zene, Ve­r­a­no­va sep­a­rate­ly un­veil ex­pan­sions; Lot­te's new ADC client

3 weeks ago
Manufacturing

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

3 weeks ago
Peer Review

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

3 weeks ago
Cell/Gene Tx
FDA+

Grail shares jump on study re­sults for can­cer test

3 weeks ago
Pharma
Diagnostics

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

3 weeks ago
Pharma
FDA+

Com­pounders lose case over semaglu­tide short­age

3 weeks ago
Pharma
Health Tech

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

3 weeks ago
R&D

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

3 weeks ago
Pharma
FDA+

Q&A: New BIO chair to steer in­dus­try through ‘ex­is­ten­tial threats’ de­spite FDA re­cep­tiv­i­ty

3 weeks ago
R&D
China

BioN­Tech stops mak­ing cell ther­a­py at Mary­land site af­ter drop­ping germ cell tu­mor in­di­ca­tion

4 weeks ago
R&D
Cell/Gene Tx

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

4 weeks ago
R&D
Discovery

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

4 weeks ago
R&D

Ten­nr rais­es $101M Se­ries C to fix fax­es with AI

4 weeks ago
Financing
Health Tech

Hu­mana de­tails plans to grow its pri­ma­ry care busi­ness as com­pet­ing clin­ics shut­ter

4 weeks ago
Deals
Health Tech

Bavar­i­an Nordic's PRV goes for $160M; Bio­mea to ad­vance GLP-1 in­to tri­als

4 weeks ago
News Briefing

Watch Post-Hoc Live: Chi­na is still the top con­ver­sa­tion starter at BIO

4 weeks ago
Editor's note
China

Ac­tio gets $66M for ex­per­i­men­tal epilep­sy and Char­cot-Marie-Tooth treat­ments

4 weeks ago
Financing

Sanofi-backed Welsh biotech se­cures $140M for neu­ropsy­chi­a­try pipeline

4 weeks ago
Financing
Startups

Mem­bers of Con­gress op­pose NI­H's pay­ment cut plan, urge ap­peals court to main­tain block

4 weeks ago
Law

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

4 weeks ago
Pharma
Law

FDA ap­proves CSL’s pro­phy­lac­tic for se­vere swelling con­di­tion

4 weeks ago
Pharma
FDA+

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

4 weeks ago
FDA+
First page Previous page 567891011 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times